istock-512543170-agreement
Choreograph / iStockphoto.com
20 February 2017Americas

Novartis in $1bn cardiovascular deal with Ionis and Akcea

Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.

The closing of the deal, which is valued at $1 billion by the parties, was announced on Thursday, February 16.

Novartis will pay Ionis and Akcea a $75 million up-front payment and make a $100 million equity investment in Ionis.

Novartis is required to make a further equity investment of $50 million in the next 18 months in either Ionis or Akcea.

Ionis and Akcea are also entitled to receive a licence fee as well as development, regulatory and commercial milestone payments for each drug as it advances.

The companies are also eligible to receive tiered royalties on net sales of each drug. The drugs are AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx.


More on this story

Americas
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

More on this story

Americas
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.